Timing of androgen-deprivation therapy for prostate cancer: still a long way to go

Affiliations

¹ Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan 20132, Italy. Electronic address: nicola.fossati@gmail.com.
² Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan 20132, Italy.

Comment

Nicola Fossati et al. Lancet Oncol. 2016 Aug.

. 2016 Aug;17(8):e313.

doi: 10.1016/S1470-2045(16)30309-6.

¹ Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan 20132, Italy. Electronic address: nicola.fossati@gmail.com.
² Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan 20132, Italy.

No abstract available

Comment on

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S. Duchesne GM, et al. Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4. Lancet Oncol. 2016. PMID: 27155740 Clinical Trial.
Timing of androgen-deprivation therapy for prostate cancer: still a long way to go - Authors' reply.
Duchesne GM. Duchesne GM. Lancet Oncol. 2016 Aug;17(8):e313-e314. doi: 10.1016/S1470-2045(16)30282-0. Lancet Oncol. 2016. PMID: 27511148 No abstract available.